Literature DB >> 12232878

Detrusor instability with equivocal obstruction: A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy.

Rintaro Machino1, Hidehiro Kakizaki, Kaname Ameda, Takashi Shibata, Hiroshi Tanaka, Shinobu Matsuura, Tomohiko Koyanagi.   

Abstract

AIMS: To elucidate whether preoperative urodynamic findings can predict outcomes of transurethral resection of the prostate (TUR-P).
METHODS: Sixty-two patients with symptomatic benign prostatic hyperplasia were categorized in three different ways based on findings of preoperative pressure-flow study (PFS) and cystometry: urodynamic obstruction (determined by the Abrams-Griffiths nomogram), detrusor instability (DI), and combination of both. Outcomes of TUR-P regarding symptom, function, and quality of life (QOL) were analyzed by changes in the International Prostate Symptom Score (I-PSS), maximum flow rate in uroflowmetry, and QOL index before and after TUR-P, respectively. Overall outcome was defined as success when all of the three categories showed successful improvement.
RESULTS: Neither urodynamic obstruction alone nor DI alone predicted outcomes of TUR-P. However, symptomatic and overall outcomes were significantly worse in patients who were not obstructed but had DI. Postoperative persistent DI was more frequently noted in patients without clear obstruction (60%) than in those with obstruction (27%). Patients with equivocal obstruction showed less satisfactory symptomatic outcomes of TUR-P when DI was accompanied. Persistent DI might be the principle cause of unfavorable outcomes.
CONCLUSIONS: Preoperative evaluation of DI is of benefit because it enhances predictive value of the PFS. Neurourol. Urodynam. 21:444-449, 2002. Copyright Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12232878     DOI: 10.1002/nau.10057

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  16 in total

Review 1.  Male overactive bladder: the role of urodynamics and anticholinergics.

Authors:  Scott MacDiarmid; Alexandra Rogers
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

2.  Persistent detrusor overactivity after transurethral resection of the prostate.

Authors:  Fadi Housami; Paul Abrams
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 3.  Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms.

Authors:  Bilal Chughtai; Vannita Simma-Chiang; Steven A Kaplan
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

4.  Overactive bladder and outlet obstruction in men.

Authors:  Doreen E Chung; Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2011-02       Impact factor: 3.092

5.  Urodynamically diagnosed detrusor hypocontractility: should transurethral resection of the prostate be contraindicated?

Authors:  Rubiao Ou; Chaojie Pan; Hui Chen; Suishan Wu; Xinghua Wei; Xiangrong Deng; Ping Tang; Keji Xie
Journal:  Int Urol Nephrol       Date:  2011-06-10       Impact factor: 2.370

Review 6.  Nocturia: aetiology and treatment in adults.

Authors:  Hasan Dani; Ashanda Esdaille; Jeffrey P Weiss
Journal:  Nat Rev Urol       Date:  2016-07-26       Impact factor: 14.432

Review 7.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 8.  Overactive bladder and men: indications for anticholinergics.

Authors:  Ricardo R González; Alexis E Te
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

Review 9.  Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment.

Authors:  William I Jaffe; Alexis E Te
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

10.  Non-Hormonal treatment of BPH/BOO.

Authors:  Nadir I Osman; Altaf Mangera; Christopher R Chapple
Journal:  Indian J Urol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.